Equities research analysts at StockNews.com began coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Stock Up 5.1 %
Shares of XXII opened at $0.11 on Friday. 22nd Century Group has a twelve month low of $0.09 and a twelve month high of $8.63. The stock has a market cap of $932,850.00, a PE ratio of 0.00 and a beta of 1.39. The business’s 50-day moving average price is $0.27 and its 200-day moving average price is $0.78.
22nd Century Group (NASDAQ:XXII – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. The company had revenue of $7.95 million during the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%.
Institutional Inflows and Outflows
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
See Also
- Five stocks we like better than 22nd Century Group
- Best Stocks Under $5.00
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Calculate Inflation Rate
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Stock Market Index and How Do You Use Them?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.